SMARCA4 and cancer: Importantly, mutations in the catalytic ATPase-DNA translocase subunit of BAF/PBAF, named BRG1 in humans, tend to be heterozygous in cancers, suggesting that they are either haploinsufficient or act through dominant mechanisms such as gain-of-function or dominant-negative interference.